Anavex Strengthens Alzheimer’s Pipeline, Obtains Exclusive Worldwide Rights to Intellectual Property

Preclinical Data Presented at 13th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy New York, NY — March 31, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s, diseases of the central nervous system (CNS) and various types of cancer,…

Anavex Reports Predicted Clinical Effect of Both ANAVEX 2-73 and ANAVEX PLUS in a Humanized Cortical Cognitive Model for Alzheimer’s Disease

New York, NY — March 27, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s, diseases of the central nervous system (CNS) and various types of cancer, today announced that a report in the current issue of peer-reviewed International Pharmaceutical…

Anavex Successfully Closes $10 Million Financing to Initiate Phase 1b/2a Alzheimer’s Clinical Trial

New York, NY — March 19, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s, diseases of the central nervous system (CNS) and various types of cancer, announced today that it has closed, as previously announced on March 13, 2014,…

Anavex Announces $10 Million Private Placement of Convertible Debentures

Secures Capital to Execute Clinical Trial Phase 1b/2a in Alzheimer’s Disease and Advance Product Portfolio New York, NY — March 13, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s, diseases of the central nervous system (CNS) and various types…

Anavex Encouraged By Scientific Data Confirming Sigma-1 Receptor Agonist Extends Survival in ALS (Lou Gehrig’s Disease)

Company to Initiate Pre-Clinical Studies of ANAVEX 2-73 in ALS Models New York, NY — March 10, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s, diseases of the central nervous system (CNS) and various types of cancer, today announced…

Anavex: Research Report Reveals Cardioprotective Action of Sigma-1 Receptor Agonists

Findings Correlate with Positive Phase 1 Safety Data for ANAVEX 2-73 New York, NY — March 4, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) is encouraged by the findings of a research report published in the current issue of peer-reviewed scientific journal Life Sciences.  Among its conclusions, the report reveals…